10-QPeriod: Q1 FY2008

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2008

Filed April 23, 2008For Securities:BIIB

Summary

Biogen Idec Inc. reported solid financial results for the first quarter of 2008, with total revenue reaching $942.2 million, a significant increase from $715.9 million in the prior year's first quarter. This growth was primarily driven by strong performance in its key products, AVONEX and TYSABRI, alongside increased revenues from its joint business arrangement with Genentech for RITUXAN. Net income for the quarter was $163.1 million, translating to diluted earnings per share of $0.54. The company highlighted continued revenue growth for TYSABRI, an increase in RITUXAN revenues, and the impact of price increases on AVONEX. However, this revenue growth was partially offset by increased operating expenses, particularly in research and development due to ongoing clinical trials and in selling, general, and administrative expenses to support sales growth. The company also noted a decrease in ZEVALIN revenue following the sale of its U.S. rights.

Key Highlights

  • 1Total revenue increased by 31.6% to $942.2 million for the three months ended March 31, 2008, compared to $715.9 million in the same period of 2007.
  • 2Net income for the quarter was $163.1 million, with diluted earnings per share of $0.54.
  • 3AVONEX sales grew 19.4% to $536.1 million, driven by price increases in the U.S. and increased unit shipments internationally.
  • 4TYSABRI sales experienced substantial growth of 284.9%, reaching $114.7 million, attributed to an increase in patient usage and approvals in new countries.
  • 5RITUXAN, through the unconsolidated joint business arrangement, contributed significantly with copromotion profits increasing by 15.8% to $158.0 million, driven by higher RITUXAN sales.
  • 6Research and Development expenses increased by 34.9% to $258.2 million, reflecting investments in various clinical trials and development projects.
  • 7The company's cash, cash equivalents, and marketable securities decreased to $1,660.9 million as of March 31, 2008, from $2,115.8 million at December 31, 2007, primarily due to debt repayment and share repurchases.

Frequently Asked Questions

Revenue growth was primarily driven by strong sales of AVONEX and TYSABRI, coupled with increased revenues from the RITUXAN joint business arrangement with Genentech. Price increases for AVONEX and increased patient uptake and international approvals for TYSABRI were key factors.

Operating expenses saw an increase, with Research and Development expenses rising by 34.9% due to ongoing clinical trials and other projects. Selling, General, and Administrative expenses also increased by 14.7%, driven by higher personnel costs to support sales growth for AVONEX and TYSABRI.

Biogen Idec maintained a strong liquidity position with $1,660.9 million in cash, cash equivalents, and marketable securities as of March 31, 2008. However, this represents a decrease from December 31, 2007, mainly due to significant debt repayment and share repurchases.

Key risks include substantial dependence on AVONEX and RITUXAN sales, the critical need for market acceptance and sales growth of TYSABRI, potential disruptions from activist shareholders, the inherent risks of drug development and commercialization, potential adverse safety events, intense competition, reliance on collaborators, and reimbursement risks from third-party payors.